Related Experiment Videos
Abstract:
In a clinicopathologic analysis of previously unreported uterine hemangiopericytomas, malignant behavior was observed in four of 21 followed patients. Recurrent disease occurred in the pelvis, abdomen, and lungs. The role of chemotherapy in the treatment of recurrences was not substantiated. No specific histologic features could be identified that correlated with malignant potential.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
[Dose constraints to organs at risk for conformational and stereotactic radiotherapy: Small bowel and duodenum].
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2017
Rethinking Menopausal Hormone Therapy After Risk-Reducing Salpingo-Oophorectomy in Women at High Risk for Breast Cancer.
Obstetrics and gynecology·2026
Hormonal Options for Perimenopause: A Clinician Toolkit.
Obstetrics and gynecology·2026
Episiotomy and Anal Sphincter Injury During Operative Vaginal Delivery in a U.S. Cohort.
Obstetrics and gynecology·2026
Small extracellular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes.
British journal of cancer·2026
Individual and systems level factors associated with odds of orchiectomy in testicular torsion in New York State.
Journal of pediatric urology·2026
USP11 exacerbates intestinal I/R injury by driving NCOA4-mediated ferritinophagy and ferroptosis via Beclin-1 deubiquitination.
International immunopharmacology·2026